title: PINP: a serum biomarker of bone formation in the rat.
abstract: Serum PINP has emerged as a reliable marker of bone turnover in humans and is routinely used to monitor bone formation. However, the effects of PTH (1-34) on bone turnover have not been evaluated following short-term treatment. We present data demonstrating that PINP is an early serum biomarker in the rat for assessing bone anabolic activity in response to treatment with PTH (1-38). Rat serum PINP levels were found to increase following as few as 6 days of treatment with PTH (1-38) and these increases paralleled expression of genes associated with bone formation, as well as, later increases in BMD. Additionally, PINP levels were unaffected by treatment with an antiresorptive bisphosphonate. PINP may be used to detect PTH-induced early bone formation in the rat and may be more generally applicable for preclinical testing of potential bone anabolic drugs.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Hale_Laura_V@Lilly.com
authors.forename: L V
authors.initials: LV
authors.lastname: Hale
authors.forename: R J Sells
authors.initials: RJ
authors.lastname: Galvin
authors.forename: J
authors.initials: J
authors.lastname: Risteli
authors.forename: Y L
authors.initials: YL
authors.lastname: Ma
authors.forename: A K
authors.initials: AK
authors.lastname: Harvey
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: R L
authors.initials: RL
authors.lastname: Cain
authors.forename: Q
authors.initials: Q
authors.lastname: Zeng
authors.forename: C A
authors.initials: CA
authors.lastname: Frolik
authors.forename: M
authors.initials: M
authors.lastname: Sato
authors.forename: A L
authors.initials: AL
authors.lastname: Schmidt
authors.forename: A G
authors.initials: AG
authors.lastname: Geiser
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D055511:CCN Intercellular Signaling Proteins; D002268:Carboxypeptidases / Q000235:genetics; D003094:Collagen / Q000235:genetics; D024042:Collagen Type I; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D015513:Oncogene Proteins / Q000235:genetics; D015675:Osteocalcin / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000494:pharmacology; D010446:Peptide Fragments / Q000097:blood* / Q000494:pharmacology; D011347:Procollagen / Q000097:blood*; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D055511:CCN Intercellular Signaling Proteins; C492066:CCN4 protein, rat; D024042:Collagen Type I; D015513:Oncogene Proteins; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011347:Procollagen; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D011994:Recombinant Proteins; C035747:parathyroid hormone (1-38); C047202:procollagen Type I N-terminal peptide; D015675:Osteocalcin; D003094:Collagen; D002268:Carboxypeptidases; C499286:Cpz protein, rat